The privately-owned Belgian drug developer Ogeda SA is to be acquired by Astellas Pharma Inc of Japan in a deal potentially valued at €800 million. Ogeda is developing products for women’s health that target G-protein coupled receptors (GPCRs). ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
